ARC-10: A phase 3 study to evaluate zimberelimab plus domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non-small-cell lung cancer.

被引：0
|
作者：
Chouaid, Christos
Ho, Gwo Fuang
Runglodvatana, Yotsawaj
He, Xian
Ahlers, Christoph Matthias
Pomponio, Debbie
Todd, Trever
Dang, Thao
Naidoo, Jarushka
机构：
[1] Ctr Hosp Intercommunal Creteil, Creteil, France
[2] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[3] Vajira Hosp, Bangkok, Thailand
[4] Arcus Biosci Inc, Hayward, CA USA
[5] Gilead Sci Inc, Foster City, CA USA
[6] Beaumont Hosp, Dublin, Ireland
[7] RCSI Univ Hlth Sci, Dublin, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9148
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ARC-10: Phase 3 Study of Zimberelimab ± Domvanalimab vs Standard Chemotherapy in FrontLine, PD-L1-High, Metastatic NSCLC
    Li, Y.
    Krishnan, K.
    Gilbert, H.
    Phuong, P.
    He, X.
    Colburn, D.
    Grossman, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1018 - S1018
  • [2] Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.
    Addeo, Alfredo
    Metro, Giulio
    Signorelli, Diego
    Economopoulou, Panagiota
    Roila, Fausto
    Banna, Giuseppe Luigi
    De Toma, Alessandro
    Camerini, Andrea
    Christopoulou, Athina
    Lo Russo, Giuseppe
    Galetta, Domenico
    Munarriz, Beatriz Jimenez
    Collazo, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris A.
    Mountzios, Giannis Socrates
    Garassino, Marina Chiara
    Friedlaender, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Docetaxel for locally advanced or metastatic non-small-cell lung cancer current data and future directions as front-line therapy
    Khuri, FR
    ONCOLOGY-NEW YORK, 2002, 16 (06): : 53 - 62
  • [4] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    Stathopoulos, G. P.
    Katis, C.
    Tsavdaridis, D.
    Dimitroulis, J.
    Karaindros, D.
    Stathopoulos, J.
    Dimou, E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 555 - 560
  • [5] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    G. P. Stathopoulos
    C. Katis
    D. Tsavdaridis
    J. Dimitroulis
    D. Karaindros
    J. Stathopoulos
    E. Dimou
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 555 - 560
  • [6] Pembrolizumab mono versus Pembrolizumab plus Chemotherapy as first-line Palliative Therapy for PD-L1-high positive Non-small Cell Lung Cancer: a Two-center Study
    Olive, E.
    Frost, N.
    Grohe, C.
    PNEUMOLOGIE, 2022, 76 : S93 - S93
  • [7] WEEKLY PACLITAXEL-CARBOPLATIN AS FRONT-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH LOCALLY ADVANCED/METASTATIC (STAGE IIIB-IV) NON-SMALL-CELL LUNG CANCER. A PHASE II STUDY
    Lanzetta, G.
    Rozzi, A.
    Di Martino, M.
    Martelli, M.
    Capalbo, C.
    Portarena, I.
    Frati, L.
    ANNALS OF ONCOLOGY, 2004, 15 : 33 - 33
  • [8] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
    Alessi, Joao Victor Machado
    Ricciuti, Biagio
    Aguilar, Elizabeth Jimenez
    Hong, Fangxin
    Wei, Zihan
    Nishino, Mizuki
    Plodkowski, Andrew J.
    Sawan, Peter
    Luo, Jia
    Rizvi, Hira
    Carter, Brett W.
    Heymach, John
    Altan, Mehmet
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] ARC-7: A phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC)
    Chaudhry, A.
    Johnson, M.
    Colburn, D.
    Gilbert, H.
    Garofalo, A.
    Paoloni, M.
    Krishnan, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S897 - S897
  • [10] Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, V
    Ardavanis, A
    Agelidou, A
    Agelidou, M
    Chandrinos, V
    Tsaroucha, E
    Toumbis, M
    Kouroussis, C
    Syrigos, K
    Polyzos, A
    Samaras, N
    Papakotoulas, P
    Christofilakis, C
    Ziras, N
    Alegakis, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2602 - 2609
12345